对于大体积良性甲状腺结节,早期第二次射频消融治疗在12个月后的结节缩小程度明显高于单次治疗。

IF 3.2 2区 医学 Q1 SURGERY
Surgery Pub Date : 2024-10-24 DOI:10.1016/j.surg.2024.06.078
Man Him Matrix Fung, Yan Luk, Brian Hung Hin Lang
{"title":"对于大体积良性甲状腺结节,早期第二次射频消融治疗在12个月后的结节缩小程度明显高于单次治疗。","authors":"Man Him Matrix Fung, Yan Luk, Brian Hung Hin Lang","doi":"10.1016/j.surg.2024.06.078","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Radiofrequency ablation (RFA) is an effective nonsurgical treatment for symptomatic benign thyroid nodules. Large-volume nodules (≥20-mL) often require 2 or more radiofrequency ablation sessions to achieve desirable shrinkage but the optimal interval between sessions remains unknown. We hypothesized that early (within 6 months) retreatment could improve nodule shrinkage. This study compared the 12-month volume reduction rate (VRR) and complications between single-session radiofrequency ablation and 2-session radiofrequency ablation within 6 months for large benign thyroid nodules.</p><p><strong>Methods: </strong>Consecutive patients with cytologically proven benign thyroid nodules ≥20 mL undergoing radiofrequency ablation were prospectively assigned to undergo either single-session (group 1) or 2-session radiofrequency ablation within 6 months (group 2). All were followed up for at least 12 months after the initial radiofrequency ablation. Volume reduction rate was calculated as (baseline - current volume)/baseline volume × 100%. Complications were documented.</p><p><strong>Results: </strong>Out of 67 nodules ≥20 mL that underwent radiofrequency ablation, 43 nodules (group 1: n = 23, group 2: n = 20) from 42 patients were analyzed. Both groups had comparable baseline nodule volumes (33.2 ± 14.9 mL vs 34.3 ± 12.5 mL) and clinical parameters (P > .05). The 6-month volume reduction rate was comparable (65.7 ± 13.2% vs 68.6 ± 13.3%, P = .264) but the 12-month volume reduction rate was significantly greater in group 2 (65.9 ± 17.1% vs 75.6 ± 11.5%, P = .019). Group 2 nodules continued to shrink from 6 to 12 months (P = .012), whereas group 1 nodules did not (P = .503). Two-session radiofrequency ablation within 6 months was the only significant factor associated with a 12-month volume reduction rate of ≥75% (odds ratio 4.375, 95% confidence interval 1.210-15.812, P = .024). No vocal cord paresis or hematoma requiring reoperation occurred.</p><p><strong>Conclusion: </strong>Early retreatment with 2-session radiofrequency ablation within 6 months was safe and led to significantly greater nodule shrinkage at 12 months than single-session radiofrequency ablation.</p>","PeriodicalId":22152,"journal":{"name":"Surgery","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Early second radiofrequency ablation treatment gave rise to significantly greater nodule shrinkage at 12 months than single-session treatment for large-volume benign thyroid nodules.\",\"authors\":\"Man Him Matrix Fung, Yan Luk, Brian Hung Hin Lang\",\"doi\":\"10.1016/j.surg.2024.06.078\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Radiofrequency ablation (RFA) is an effective nonsurgical treatment for symptomatic benign thyroid nodules. Large-volume nodules (≥20-mL) often require 2 or more radiofrequency ablation sessions to achieve desirable shrinkage but the optimal interval between sessions remains unknown. We hypothesized that early (within 6 months) retreatment could improve nodule shrinkage. This study compared the 12-month volume reduction rate (VRR) and complications between single-session radiofrequency ablation and 2-session radiofrequency ablation within 6 months for large benign thyroid nodules.</p><p><strong>Methods: </strong>Consecutive patients with cytologically proven benign thyroid nodules ≥20 mL undergoing radiofrequency ablation were prospectively assigned to undergo either single-session (group 1) or 2-session radiofrequency ablation within 6 months (group 2). All were followed up for at least 12 months after the initial radiofrequency ablation. Volume reduction rate was calculated as (baseline - current volume)/baseline volume × 100%. Complications were documented.</p><p><strong>Results: </strong>Out of 67 nodules ≥20 mL that underwent radiofrequency ablation, 43 nodules (group 1: n = 23, group 2: n = 20) from 42 patients were analyzed. Both groups had comparable baseline nodule volumes (33.2 ± 14.9 mL vs 34.3 ± 12.5 mL) and clinical parameters (P > .05). The 6-month volume reduction rate was comparable (65.7 ± 13.2% vs 68.6 ± 13.3%, P = .264) but the 12-month volume reduction rate was significantly greater in group 2 (65.9 ± 17.1% vs 75.6 ± 11.5%, P = .019). Group 2 nodules continued to shrink from 6 to 12 months (P = .012), whereas group 1 nodules did not (P = .503). Two-session radiofrequency ablation within 6 months was the only significant factor associated with a 12-month volume reduction rate of ≥75% (odds ratio 4.375, 95% confidence interval 1.210-15.812, P = .024). No vocal cord paresis or hematoma requiring reoperation occurred.</p><p><strong>Conclusion: </strong>Early retreatment with 2-session radiofrequency ablation within 6 months was safe and led to significantly greater nodule shrinkage at 12 months than single-session radiofrequency ablation.</p>\",\"PeriodicalId\":22152,\"journal\":{\"name\":\"Surgery\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.surg.2024.06.078\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.surg.2024.06.078","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

摘要

简介射频消融(RFA)是治疗无症状良性甲状腺结节的一种有效的非手术疗法。大体积结节(≥20 毫升)通常需要 2 次或更多次射频消融治疗才能达到理想的缩小效果,但两次治疗之间的最佳间隔时间仍然未知。我们假设早期(6 个月内)再治疗可以改善结节的缩小。本研究比较了单次射频消融和 6 个月内两次射频消融治疗甲状腺大良性结节的 12 个月体积缩小率(VRR)和并发症:对连续接受射频消融术的细胞学证实甲状腺良性结节≥20 mL的患者进行前瞻性分配,在6个月内接受单次射频消融术(第1组)或2次射频消融术(第2组)。所有患者均在首次射频消融术后接受了至少 12 个月的随访。体积缩小率的计算方法为(基线体积-当前体积)/基线体积×100%。并发症均有记录:在接受射频消融术的 67 个≥20 mL 的结节中,对 42 名患者的 43 个结节(第 1 组:n = 23,第 2 组:n = 20)进行了分析。两组患者的基线结节体积(33.2 ± 14.9 mL vs 34.3 ± 12.5 mL)和临床参数相当(P > .05)。6 个月的体积缩小率相当(65.7 ± 13.2% vs 68.6 ± 13.3%,P = .264),但第 2 组 12 个月的体积缩小率明显更高(65.9 ± 17.1% vs 75.6 ± 11.5%,P = .019)。从 6 个月到 12 个月,第 2 组结节继续缩小(P = .012),而第 1 组结节没有缩小(P = .503)。6 个月内两次射频消融是 12 个月体积缩小率≥75% 的唯一显著相关因素(几率比 4.375,95% 置信区间 1.210-15.812,P = .024)。没有发生需要再次手术的声带瘫痪或血肿:结论:与单次射频消融术相比,6 个月内进行 2 次射频消融术的早期再治疗是安全的,而且在 12 个月时结节的缩小程度明显更大。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Early second radiofrequency ablation treatment gave rise to significantly greater nodule shrinkage at 12 months than single-session treatment for large-volume benign thyroid nodules.

Introduction: Radiofrequency ablation (RFA) is an effective nonsurgical treatment for symptomatic benign thyroid nodules. Large-volume nodules (≥20-mL) often require 2 or more radiofrequency ablation sessions to achieve desirable shrinkage but the optimal interval between sessions remains unknown. We hypothesized that early (within 6 months) retreatment could improve nodule shrinkage. This study compared the 12-month volume reduction rate (VRR) and complications between single-session radiofrequency ablation and 2-session radiofrequency ablation within 6 months for large benign thyroid nodules.

Methods: Consecutive patients with cytologically proven benign thyroid nodules ≥20 mL undergoing radiofrequency ablation were prospectively assigned to undergo either single-session (group 1) or 2-session radiofrequency ablation within 6 months (group 2). All were followed up for at least 12 months after the initial radiofrequency ablation. Volume reduction rate was calculated as (baseline - current volume)/baseline volume × 100%. Complications were documented.

Results: Out of 67 nodules ≥20 mL that underwent radiofrequency ablation, 43 nodules (group 1: n = 23, group 2: n = 20) from 42 patients were analyzed. Both groups had comparable baseline nodule volumes (33.2 ± 14.9 mL vs 34.3 ± 12.5 mL) and clinical parameters (P > .05). The 6-month volume reduction rate was comparable (65.7 ± 13.2% vs 68.6 ± 13.3%, P = .264) but the 12-month volume reduction rate was significantly greater in group 2 (65.9 ± 17.1% vs 75.6 ± 11.5%, P = .019). Group 2 nodules continued to shrink from 6 to 12 months (P = .012), whereas group 1 nodules did not (P = .503). Two-session radiofrequency ablation within 6 months was the only significant factor associated with a 12-month volume reduction rate of ≥75% (odds ratio 4.375, 95% confidence interval 1.210-15.812, P = .024). No vocal cord paresis or hematoma requiring reoperation occurred.

Conclusion: Early retreatment with 2-session radiofrequency ablation within 6 months was safe and led to significantly greater nodule shrinkage at 12 months than single-session radiofrequency ablation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Surgery
Surgery 医学-外科
CiteScore
5.40
自引率
5.30%
发文量
687
审稿时长
64 days
期刊介绍: For 66 years, Surgery has published practical, authoritative information about procedures, clinical advances, and major trends shaping general surgery. Each issue features original scientific contributions and clinical reports. Peer-reviewed articles cover topics in oncology, trauma, gastrointestinal, vascular, and transplantation surgery. The journal also publishes papers from the meetings of its sponsoring societies, the Society of University Surgeons, the Central Surgical Association, and the American Association of Endocrine Surgeons.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信